Moreover, the suppression of the cGAS-STING pathway found in cancer cells (Suter et al., 2021) could be another factor leading to the lack of production of the M1 phenotype-related cytokines in the B16-F10 cells upon treatment with the DMXAA formulations. This evidence concerns the gene CGAS and cancer.